Drugs · acquisition-cost intelligence
Zylet
loteprednol etabonate and tobramycin· ingredient tobramycinAntibiotics· LOTEPREDNOL ETABONATE 5 mg/mL; TOBRAMYCIN 3 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$64.48
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-01-012026-05-20
Same-ingredient options by acquisition cost
Other tobramycin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Tobramycin | $0.64108 | −$63.83 |
| Tobramycin | $0.64108 | −$63.83 |
| Tobramycin | $1.02 | −$63.46 |
| Kitabis Pak | $1.08 | −$63.39 |
| tobramycin and dexamethasone | $4.96 | −$59.51 |
| Tobradex ST | $46.67 | −$17.80 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.